A randomized, double-blind clinical trial of a herbal formulation (GlycaCare-II) for the management of type 2 diabetes in comparison with metformin

Table 2 Lipid profile for GlycaCare-II and Metformin

Group	Product	Prediabetic			Newly diagnosed diabetic
Day		0	120	P-value	0	120	P-value
Parameter		Mean ± SD	Mean ± SD	P-value	Mean ± SD	Mean ± SD	P-value
TC (mg/dl)	GlycaCare-II	194.29 ± 22.26	180.88 ± 20.35	0.0761	208.96 ± 25.18	187.04 ± 16.27	0.0008↓*
TC (mg/dl)	Metformin	184.17 ± 14.78	179.00 ± 15.71	0.4153	198.31 ± 12.84	185.69 ± 15.10	0.0162↓*
TG (mg/dl)	GlycaCare-II	162.00 ± 21.98	157.00 ± 18.88	0.4819	172.13 ± 18.44	157.13 ± 14.61	0.0031↓*
TG (mg/dl)	Metformin	151.50 ± 28.79	152.42 ± 13.60	0.9212	162.88 ± 14.87	158.31 ± 18.82	0.4519
HDL (mg/dl)	GlycaCare-II	38.82 ± 4.45	36.29 ± 3.84	0.0855	41.75 ± 4.87	37.46 ± 3.30	0.0008↓*
HDL (mg/dl)	Metformin	39.42 ± 6.84	35.17 ± 2.37	0.0542↓	40.00 ± 3.14	37.257 ± 3.47	0.0255↓*
LDL (mg/dl)	GlycaCare-II	120.41 ± 19.92	113.35 ± 13.29	0.2330	132.21 ± 17.81	118.13 ± 11.10	0.0019↓*
LDL (mg/dl)	Metformin	115.33 ± 10.06	110.92 ± 14.19	0.3893	125.88 ± 13.88	114.19 ± 12.29	0.0172↓*
VLDL (mg/dl)	GlycaCare-II	32.47 ± 4.56	31.24 ± 3.73	0.3957	34.58 ± 3.69	31.46 ± 2.81	0.0019↓*
VLDL (mg/dl)	Metformin	30.42 ± 5.87	30.17 ± 3.97	0.9038	32.99 ± 3.06	31.63 ± 3.91	0.2819

SD Standard deviation, TC total cholesterol, TG TriGlycerides, HDL high-density lipoproteins, LDL low-density lipoproteins, VLDL very low-density lipoproteins, ↑* = Statistically significant increase (p < 0.05), ↓* = Statistically significant decrease (p < 0.05), No. of Subjects (Prediabetics: GlycaCare-II–17 & Metformin–12, Newly diagnosed diabetic: GlycaCare-II-24 & Metformin-16)

ISSN: 1758-5996